Cargando…
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
Myostatin is a negative regulator of skeletal muscle and has become a therapeutic target for muscle atrophying disorders. Although previous inhibitors of myostatin offered promising preclinical data, these therapies demonstrated a lack of specificity toward myostatin signaling and have shown limited...
Autores principales: | Welsh, Brian T., Cote, Shaun M., Meshulam, Deborah, Jackson, Justin, Pal, Ajai, Lansita, Janice, Kalra, Ashish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326894/ https://www.ncbi.nlm.nih.gov/pubmed/34255983 http://dx.doi.org/10.1177/10915818211025477 |
Ejemplares similares
-
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
por: Barrett, Doreen, et al.
Publicado: (2021) -
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation
por: Cote, Shaun M., et al.
Publicado: (2019) -
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
por: Welsh, Brian T., et al.
Publicado: (2021) -
Population toxicokinetics of benzene.
por: Bois, F Y, et al.
Publicado: (1996) -
Microcystin Toxicokinetics, Molecular Toxicology, and Pathophysiology in Preclinical Rodent Models and Humans
por: Arman, Tarana, et al.
Publicado: (2021)